PT88541A - Processo para a preparacao de composicoes sob a forma de gel contendo factores de crescimento - Google Patents

Processo para a preparacao de composicoes sob a forma de gel contendo factores de crescimento

Info

Publication number
PT88541A
PT88541A PT88541A PT8854188A PT88541A PT 88541 A PT88541 A PT 88541A PT 88541 A PT88541 A PT 88541A PT 8854188 A PT8854188 A PT 8854188A PT 88541 A PT88541 A PT 88541A
Authority
PT
Portugal
Prior art keywords
compositions
preparation
growth factors
gel containing
containing growth
Prior art date
Application number
PT88541A
Other languages
English (en)
Inventor
Rao S Bezwada
Shalaby W Shalaby
Amy L Finkenaur
Jonathan M Cohen
Elisabeth A Sandoval
Richard L Kronenthal
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc filed Critical Ethicon Inc
Publication of PT88541A publication Critical patent/PT88541A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT88541A 1987-09-18 1988-09-16 Processo para a preparacao de composicoes sob a forma de gel contendo factores de crescimento PT88541A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9881687A 1987-09-18 1987-09-18
US23348388A 1988-08-19 1988-08-19

Publications (1)

Publication Number Publication Date
PT88541A true PT88541A (pt) 1989-07-31

Family

ID=26795141

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88541A PT88541A (pt) 1987-09-18 1988-09-16 Processo para a preparacao de composicoes sob a forma de gel contendo factores de crescimento

Country Status (9)

Country Link
US (1) US5427778A (pt)
EP (1) EP0312208A1 (pt)
JP (1) JPH02112A (pt)
KR (1) KR890004720A (pt)
AU (1) AU2223588A (pt)
GR (1) GR1000250B (pt)
MX (1) MX169808B (pt)
NZ (1) NZ226171A (pt)
PT (1) PT88541A (pt)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124316A (en) * 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
EP0386960A3 (en) * 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5271943A (en) 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
LU87624A1 (fr) * 1989-11-16 1991-07-22 Oreal Composition pharmaceutique et/ou cosmetique contenant un facteur de croissance hypophysaire(hdgf)stabilise par de l'elastine soluble
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
BR9106377A (pt) * 1990-04-26 1993-04-27 Cytrx Corp Composicao e processo para o tratamento topico de tecido lesado ou enfermo
JP3377524B2 (ja) * 1990-05-30 2003-02-17 プレジデント アンド フェロウズ オブ ハーバード カレッジ 創傷治癒
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
GB2248842A (en) * 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
US5955436A (en) * 1990-11-20 1999-09-21 Alcon Laboratories, Inc. Use of platelet derived growth factor to enhance wound healing
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
CA2097063C (en) * 1990-11-27 2006-08-08 Howard P. Greisler Tissue sealant and growth factor containing compositions that promote accelerated wound healing
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US7189410B1 (en) 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
SE501217C2 (sv) * 1990-12-06 1994-12-12 Skandigen Ab Cellproliferationsmatris och användning därav
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
GB9102107D0 (en) * 1991-01-31 1991-03-13 Erba Carlo Spa Stabilisation of fibroblast growth factor using a polysaccharide
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
GR920100122A (el) * 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
EP0510270A1 (en) * 1991-04-25 1992-10-28 LINDSTROM, Richard L. Viscoelastic solution
EP0516026A1 (en) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel and method of producing same
JP3305355B2 (ja) * 1991-06-03 2002-07-22 三菱化学株式会社 肝実質細胞増殖剤
TW318142B (pt) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
CA2089487A1 (en) * 1991-06-14 1992-12-15 Suk-Zu Song Collagen film drug delivery for proteins
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
FR2678832B1 (fr) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
BR9206630A (pt) * 1991-10-16 1995-04-25 Richardson Vicks Inc Gel cosmético aquoso de baixo pH contendo derivados não iônicos de poliacrilamida
SK43294A3 (en) * 1991-10-16 1995-01-12 Richardson Vicks Inc Agent improving the penetration of treatments at surface application
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
EP0539087A1 (en) * 1991-10-21 1993-04-28 Merck & Co. Inc. Stabilized topical acidic fibroblast growth factor formulation
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
DE4209722C3 (de) * 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
ATE152630T1 (de) * 1992-07-28 1997-05-15 Procter & Gamble Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält
FR2699545B1 (fr) * 1992-12-18 1995-01-27 Oreal Agent gélifiant résultant de l'association d'un chitosane et d'un alginate d'alkyle ou d'hydroxyalkyle et son utilisation dans la préparation de compositions cosmétiques et pharmaceutiques.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
DE69427908T2 (de) * 1993-05-31 2001-11-22 Kaken Pharmaceutical Co., Ltd. Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
US5989536A (en) * 1993-07-03 1999-11-23 The Procter & Gamble Company Personal cleansing compositions containing alkoxylated ether and cationic ammonium salt for deposition of active agent upon the skin
CU22405A1 (es) * 1993-07-05 1996-01-31 Cigb Composicion cosmetica para el cuidado de la piel
AU697894B2 (en) * 1993-11-09 1998-10-22 Neurospheres Holdings Ltd (In situ) modification and manipulation of stem cells of the central nervous system
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US20030105007A1 (en) * 1995-06-07 2003-06-05 Andre Beaulieu PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
JPH11507697A (ja) * 1995-06-09 1999-07-06 エヌ． ドロハン，ウィリアム キチンヒドロゲル、それらの製造方法及び利用
JPH09143093A (ja) * 1995-11-17 1997-06-03 Hoechst Japan Ltd 軟骨・骨誘導性修復用材料
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US5985320A (en) * 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
AU729086C (en) * 1996-03-05 2006-12-14 Depuy Acromed, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
KR100231805B1 (ko) * 1997-01-09 1999-12-01 윤재승 인간상피세포 성장인자를 함유하는 피부외용제 조성물
US6630442B1 (en) * 1997-01-10 2003-10-07 Theodore Hersh Reparatives for chemosurgery and laser (thermal) therapy
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
US6138683A (en) * 1997-09-19 2000-10-31 Thione International, Inc. Smokeless tobacco products containing antioxidants
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
BR9815708B1 (pt) * 1998-03-07 2010-10-19 composição tópica para tratar lesões cutáneas.
US20030147860A1 (en) 2002-02-07 2003-08-07 Marchosky J. Alexander Compositions and methods for forming and strengthening bone
US6497893B1 (en) 1999-06-30 2002-12-24 Kimberly-Clark Worldwide, Inc. Silk protein treatment composition and treated substrate for transfer to skin
JP2002524425A (ja) * 1998-09-04 2002-08-06 サイオス インコーポレイテッド 増殖因子の徐放性投与のためのヒドロゲル組成物
IL142432A0 (en) 1998-10-05 2002-03-10 Penn State Res Found Compositions and methods for enhancing receptor-mediated cellular internalization
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US6645947B1 (en) 1999-05-20 2003-11-11 Chitogenics, Inc. Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
DE19925519A1 (de) 1999-06-04 2000-12-07 Lohmann Therapie Syst Lts Wundauflage zur gesteuerten Abgabe von Wirkstoff an Wunden und Verfahren zu ihrer Herstellung
AU782394B2 (en) * 1999-06-29 2005-07-21 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
US6500443B1 (en) * 1999-06-30 2002-12-31 Kimberly-Clark Worldwide, Inc. Delivery of a sacrificial substrate to inhibit protease permeation into skin
US6506394B1 (en) 1999-06-30 2003-01-14 Kimberly-Clark Worldwide, Inc. Delivery of a botanical extract to a treated substrate for transfer to skin
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
DE19957388A1 (de) 1999-11-24 2001-06-13 Michael Sittinger Chondroinduktive und implantierbare Substrate zur Knorpelheilung und -protektion
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
EP1938799B1 (en) * 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
EP1283210A4 (en) 2000-04-19 2003-08-06 Shionogi & Co PROCESS FOR THE PREPARATION OF SULFANIMIDE DERIVATIVES AND CRYSTALS THEREOF
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US6503524B1 (en) 2000-06-16 2003-01-07 Kimberly-Clark Worldwide, Inc. Delivery of a skin health benefit agent to a treated substrate for transfer to skin
TWI305778B (en) 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
CU23043A1 (es) * 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
AU2003213210A1 (en) 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic formulation with gum system
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7265097B2 (en) 2002-08-20 2007-09-04 Chitogenics, Inc. Methods of drug delivery using sulphated chitinous polymers
EP1545636B1 (en) 2002-09-10 2015-01-07 The American National Red Cross Hemostatic dressing
JP2006347883A (ja) * 2003-09-08 2006-12-28 Neetec:Kk 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物
US20120283232A9 (en) * 2003-11-12 2012-11-08 Zhengjun Wang Process for making a pharmaceutical composition
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005107723A2 (en) * 2004-05-06 2005-11-17 Rashid Buttar Transdermal delivery systems and transdermal chelation preparations
ITMI20041376A1 (it) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006028361A1 (es) * 2004-09-09 2006-03-16 Arturo Jimenez Bayardo Implantes y microesferas de liberación prolongada de fármacos de uso oftálmico y metodos para prepararlos
WO2006030887A1 (ja) * 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
MX2007014856A (es) * 2005-05-27 2008-02-21 Bharat Biotech Int Ltd Composicion de factor de crecimiento epidermico, un proceso para el mismo y su aplicacion.
JP2008546707A (ja) * 2005-06-17 2008-12-25 ジェネンテック・インコーポレーテッド 創傷治癒
KR100748390B1 (ko) * 2005-11-14 2007-08-10 주식회사 대웅 상피세포성장인자를 포함하는 상처치료용 서방성 필름 제형
KR100687281B1 (ko) * 2005-11-30 2007-02-27 한국과학기술연구원 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
JP5965573B2 (ja) 2006-08-04 2016-08-10 エスティービー リミテッド 創傷組織を治療するための固体包帯材
CA2662581C (en) 2006-09-13 2018-01-30 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
WO2009020612A1 (en) 2007-08-06 2009-02-12 Stb Lifesaving Technologies, Inc. Methods and dressing for sealing internal injuries
JP5123718B2 (ja) * 2008-04-15 2013-01-23 株式会社ゼロワン 茶殻等リサイクルシステム
IT1394690B1 (it) 2008-10-23 2012-07-13 Carli De Metodo di trattamento dermocosmetico della cute mediante applicazione di composizioni contenenti ngf.
CN102811704A (zh) * 2010-01-06 2012-12-05 奥夫莱夫塔埃克尼公司 稳定化的植物来源的生长因子在皮肤护理中的使用方法
EP2353624A1 (en) 2010-02-10 2011-08-10 Université de la Méditerranée - Aix-Marseille II Embolic material, its process of preparation and its therapeutical uses thereof
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
EP2758031A1 (en) 2011-09-22 2014-07-30 Bausch & Lomb Incorporated Ophthalmic gel compositions
EP3279324B1 (en) 2011-10-11 2021-02-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Exon skipping therapy for dystrophic epidermolysis bullosa
ES2639832T3 (es) 2011-11-29 2017-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones farmacéuticas para el tratamiento de la enfermedad de Darier
CN102512357A (zh) * 2012-01-11 2012-06-27 厦门大学 一种神经生长因子眼用凝胶及其制备方法
AU2012388711B2 (en) 2012-08-31 2015-12-17 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
AU2014254388B2 (en) * 2013-03-15 2019-04-04 Synedgen Inc. Compositions and methods of use for wound healing
ES2676023T3 (es) 2013-03-15 2018-07-16 F. Hoffmann-La Roche Ag Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
AU2015332556B2 (en) 2014-10-14 2021-04-29 Samuel Lynch Compositions for treating wounds
EP3470059B1 (en) 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
US10350223B2 (en) 2015-03-03 2019-07-16 Richard W. Yee Compositions and methods for treating ocular diseases
WO2016170382A1 (en) 2015-04-23 2016-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
US20180353486A1 (en) 2015-12-01 2018-12-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of darier disease
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
WO2019002168A1 (en) 2017-06-26 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
AU2019212709A1 (en) 2018-01-26 2020-08-13 Genentech, Inc. IL-22 Fc fusion proteins and methods of use
KR20200125590A (ko) 2018-01-26 2020-11-04 제넨테크, 인크. 조성물 및 사용 방법
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
KR20200123118A (ko) 2018-02-21 2020-10-28 제넨테크, 인크. IL-22 Fc 융합 단백질로 치료를 위한 투약
WO2020049327A1 (en) 2018-09-05 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of hidradenitis suppurativa in patients in need thereof
EP3856228B1 (en) 2018-09-27 2023-03-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Tafa4 polypeptide for use for reducing skin inflammation
US12491186B2 (en) 2018-10-04 2025-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) EGFR inhibitors for treating keratodermas
US20210378995A1 (en) 2018-10-10 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
EP3955920A1 (en) 2019-04-16 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2020239623A1 (en) 2019-05-24 2020-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ngal inhibitors for the treating chronic wound
US20220249426A1 (en) 2019-07-24 2022-08-11 Inserm (Institut National De La Santé Et De La Recherch Médicale) Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
CA3160126A1 (en) * 2019-11-06 2021-05-14 Sol-Gel Technologies Ltd. Method of treating palmoplantar keratoderma
EP4259794A1 (en) 2020-12-10 2023-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Substances and methods for treating dystrophic epidermolysis bullosa
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2047874A6 (pt) * 1969-06-10 1971-03-19 Nouvel Lucien
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
AU3298184A (en) * 1983-09-13 1986-09-11 Ed Giestlich Sohne A.G. Fur Chemische Industrie Topically administrable pharmaceutical compositions
EP0140998B1 (en) * 1983-11-02 1989-11-15 Nihon Chemical Research Kabushiki Kaisha Ophthalmic preparations
CH662944A5 (it) * 1984-10-18 1987-11-13 Pier Luigi Prof Dr Luisi Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione.
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing

Also Published As

Publication number Publication date
US5427778A (en) 1995-06-27
GR880100617A (en) 1989-06-22
GR1000250B (el) 1992-05-12
AU2223588A (en) 1989-03-23
NZ226171A (en) 1990-06-26
KR890004720A (ko) 1989-05-09
JPH02112A (ja) 1990-01-05
EP0312208A1 (en) 1989-04-19
MX169808B (es) 1993-07-27

Similar Documents

Publication Publication Date Title
PT88541A (pt) Processo para a preparacao de composicoes sob a forma de gel contendo factores de crescimento
PT80028B (pt) Processo para a preparacao de composicoes detergentes sob a forma de gel
PT88538A (pt) Processo para a preparacao de composicoes liofilizadas estaveis contendo factores de crescimento
BR8805820A (pt) Processo para a preparacao de uma composicao polimerica
PT83756B (pt) Processo para a preparacao de composicoes farmaceuticas com libertacao controlada
PT91731A (pt) Processo para a preparacao de composicoes farmaceuticas contendo ciclosporinas
MX11563A (es) Proceso mejorado para preparar composiciones oleaginosas estables
BR8802484A (pt) Processo para a preparacao de isocianatos
KR920700231A (ko) 히알루론산 회합체를 함유하는 신규 조성물 및 그 제조방법
PT88044A (pt) Processo para a preparacao de acidos tetra-hidrocarbazole-1-alcanoicos
PT82747A (de) Verfahren zur herstellung von kristallinen alkalischichtsilikaten
BR8804284A (pt) Processo para a preparacao de acidos etercarboxilicos
PT89075A (pt) Processo para a preparacao de diacidos diarilestiril-quinolinicos
PT90051A (pt) Processo para a preparacao de composicoes contendo poliesteres hidrofilicos modificados
PT89166A (pt) Processo para a preparacao de composicoes de borracha modificada
IT8647723A0 (it) Procedimento per la fabbricazione di articoli in poliesteri parzialmente cristallini
BR8800430A (pt) Processo para a preparacao de uma composicao termoplastica
PT89039A (pt) Processo para a preparacao de l-ramnose
PT90435A (pt) Processo aperfeicoado para a preparacao de uma cetimina
PT82435B (pt) Processo para a preparacao de compostos intermedios utilizados na sintese de antibioticos carbapenemicos
BR8905441A (pt) Processo para preparacao de composto
PT88614A (pt) Processo para a preparacao de antagonistas do factor activador de plaquetas di-hidropiridinicos
PT88181A (pt) Processo para a preparacao de derivados aralquilaminoalcoxifenilo
PT89142A (pt) Processo para a preparacao de cristais de cefem
BR8602462A (pt) Processo para preparacao de composicoes plasto-elastomericas